Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,742,165 shares of the company's stock after selling 159,985 shares during the quarter. Vanguard Group Inc. owned approximately 8.64% of Travere Therapeutics worth $117,449,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in TVTX. R Squared Ltd purchased a new position in Travere Therapeutics during the fourth quarter worth about $53,000. Victory Capital Management Inc. purchased a new position in shares of Travere Therapeutics during the 4th quarter worth about $182,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Travere Therapeutics in the fourth quarter worth approximately $192,000. Entropy Technologies LP purchased a new stake in Travere Therapeutics in the fourth quarter valued at approximately $214,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Travere Therapeutics in the fourth quarter valued at approximately $217,000.

Travere Therapeutics Stock Up 7.5 %

NASDAQ:TVTX traded up $1.01 on Friday, reaching $14.50. The stock had a trading volume of 1,615,914 shares, compared to its average volume of 1,518,708. The company has a 50-day moving average of $19.60 and a 200 day moving average of $18.59. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.29 billion, a P/E ratio of -3.54 and a beta of 0.84. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $25.29.

Remove Ads

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The business had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. On average, research analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Analysts Set New Price Targets

TVTX has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Travere Therapeutics in a report on Thursday, April 3rd. JPMorgan Chase & Co. boosted their price target on Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Bank of America raised their price objective on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. HC Wainwright lifted their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, January 15th. Finally, Evercore ISI increased their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $31.62.

Insider Buying and Selling

In other Travere Therapeutics news, SVP William E. Rote sold 2,437 shares of the firm's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the sale, the senior vice president now directly owns 83,170 shares in the company, valued at approximately $1,618,488.20. This trade represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Christopher R. Cline sold 5,192 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $104,463.04. Following the transaction, the chief financial officer now owns 90,038 shares of the company's stock, valued at $1,811,564.56. This represents a 5.45 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 188,829 shares of company stock worth $4,146,997. Insiders own 4.06% of the company's stock.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.